Mesenchymal stromal cells protect against caspase 3-mediated apoptosis of CD19+ peripheral B cells through contact-dependent upregulation of VEGF

Stem Cells and Development

Volumn 24, Issue 20, 2015, Pages 2391-2402

  Healy, Marc E ^a   Bergin, Ronan ^a   Mahon, Bernard P ^a   English, Karen ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CASPASE 3; CD19 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR; NOTCH RECEPTOR; PLERIXAFOR; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; CASP3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD; CELL CONTACT; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEDIATOR; MESENCHYMAL STROMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; BONE MARROW CELL; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; NATURAL KILLER CELL; PHYSIOLOGY; T LYMPHOCYTE; TRANSCRIPTION INITIATION; UPREGULATION;

ANTIGENS, CD19; APOPTOSIS; B-LYMPHOCYTES; BONE MARROW CELLS; CASPASE 3; CELL PROLIFERATION; HUMANS; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943547145     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2015.0089     Document Type: Article

References (55)

1. Barry FP, JM Murphy, K English and BP Mahon. (2005). Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 14:252-265.
2. da Silva Meirelles L, AI Caplan and NB Nardi. (2008). In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26:2287-2299.
3. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
4. English K, FP Barry, CP Field-Corbett and BP Mahon. (2007). IFN-gamma and TNF-Alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 110:91-100.
5. Tobin LM, ME Healy, K English and BP Mahon. (2013). Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol 172:333-348.
6. Wang Q, B Sun, D Wang, Y Ji, Q Kong, G Wang, J Wang, W Zhao, L Jin and H Li. (2008). Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand J Immunol 68:607-615.
7. English K, FP Barry and BP Mahon. (2008). Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 115:50-58.
8. Spaggiari GM, H Abdelrazik, F Becchetti and L Moretta. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576-6583.
9. Spaggiari GM, A Capobianco, H Abdelrazik, F Becchetti, MC Mingari and L Moretta. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111:1327-1333.
10. Noone C, A Kihm, K English, S O'Dea and BP Mahon. (2013). IFN-g stimulated human umbilical-Tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev 22:3003-3014.
11. Ryan JM, F Barry, JM Murphy and BP Mahon. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353-363.
12. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, B Smith and A Bartholomew. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
13. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
14. Tabera S, JA Perez-Simon, M Diez-Campelo, LI Sanchez-Abarca, B Blanco, A Lopez, A Benito, E Ocio, FM Sanchez-Guijo, C Caneizo and JF San Miguel. (2008). The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 93:1301-1309.
15. Rasmusson I, K Le Blanc, B Sundberg and O Ringden. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 65:336-343.
16. Traggiai E, S Volpi, F Schena, M Gattorno, F Ferlito, L Moretta and A Martini. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26:562-569.
17. Comoli P, F Ginevri, R Maccario, MA Avanzini, M Marconi, A Groff, A Cometa, M Cioni, L Porretti, et al. (2008). Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 23:1196-1202.
18. Franquesa M, MJ Hoogduijn, O Bestard and JM Grinyo. (2012). Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 3:212.
19. Kiel MJ and SJ Morrison. (2008). Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 8:290-301.
20. MacLennan ICM. (1995). Autoimmunity: deletion of autoreactive B cells. Curr Biol 5:103-106.
21. Franquesa M, FK Mensah, R Huizinga, T Strini, L Boon, E Lombardo, O DelaRosa, JD Laman, JMGrinyo, et al. (2014). Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 33:880-891.
22. Rosado MM, ME Bernardo, M Scarsella, A Conforti, E Giorda, S Biagini, S Cascioli, F Rossi, I Guzzo, et al. (2014). Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev 24:93-103.
23. Barry FP and JM Murphy. (2004). Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 36:568-584.
24. Pieper K, B Grimbacher and H Eibel. (2013). B-cell biology and development. J Allergy Clin Immunol 131:959-971.
25. Mendez-Ferrer S, TV Michurina, F Ferraro, AR Mazloom, BD Macarthur, S Lira, DT Scadden, A Ma'ayan, GN Enikolopov and PS Frenette. (2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466:829-834.
26. Schneider P, F MacKay, V Steiner, K Hofmann, JL Bodmer, N Holler, C Ambrose, P Lawton, S Bixler, et al. (1999). BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-1756.
27. Wang H, T Chen, T Ding, P Zhu, X Xu, L Yu and Y Xie. (2011). Adipogenic differentiation alters the immunoregulatory property of mesenchymal stem cells through BAFF secretion. Hematology 16:313-323.
28. Radtke F, A Wilson and HR MacDonald. (2004). Notch signaling in T-And B-cell development. Curr Opin Immunol 16:174-179.
29. Thomas M, M Calamito, B Srivastava, I Maillard, WS Pear and D Allman. (2007). Notch activity synergizes with Bcell-receptor and CD40 signaling to enhance B-cell activation. Blood 109:3342-3350.
30. Nwabo Kamdje AH, F Mosna, F Bifari, V Lisi, G Bassi, G Malpeli, M Ricciardi, O Perbellini, MT Scupoli, G Pizzolo and M Krampera. (2011). Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood 118:380-389.
31. Chen L, W Zhang, H Yue, Q Han, B Chen, M Shi, J Li, B Li, S You, Y Shi and RC Zhao. (2007). Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev 16:719-731.
32. Del Papa B, P Sportoletti, D Cecchini, E Rosati, C Balucani, S Baldoni, K Fettucciari, P Marconi, MF Martelli, F Falzetti and M Di Ianni. (2013). Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction. Eur J Immunol 43:182-187.
33. Cahill EF, LM Tobin, F Carty, BP Mahon and K English. (2015). Jagged-1 is required for the expansion of CD4(+) CD25(+) FoxP3(+) regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther 6:19.
34. Gospodarowicz D and K Lau. (1989). Pituitary follicular cells secrete both vascular endothelial growth factor and follistatin. Biochem Biophys Res Commun 165:292-298.
35. Beckermann BM, G Kallifatidis, A Groth, D Frommhold, A Apel, J Mattern, AV Salnikov, G Moldenhauer, W Wagner, et al. (2008). VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99:622-631.
36. Gupta K, S Kshirsagar, W Li, L Gui, S Ramakrishnan, P Gupta, PY Law and RP Hebbel. (1999). VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247:495-504.
37. Abid MR, S Guo, T Minami, KC Spokes, K Ueki, C Skurk, K Walsh and WC Aird. (2004). Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol 24:294-300.
38. Zhou H, XM Li, J Meinkoth and RN Pittman. (2000). Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 151:483-494.
39. Nie Y, J Waite, F Brewer, MJ Sunshine, DR Littman and YR Zou. (2004). The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med 200:1145-1156.
40. Liang Z, J Brooks, M Willard, K Liang, Y Yoon, S Kang and H Shim. (2007). CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359:716-722.
41. De Luca A, M Gallo, D Aldinucci, D Ribatti, L Lamura, A D'Alessio, R De Filippi, A Pinto and N Normanno. (2011). Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol 226:2131-2138.
42. Duijvestein M, ACW Vos, H Roelofs, ME Wildenberg, BB Wendrich, HW Verspaget, EMC Kooy-Winkelaar, F Koning, JJ Zwaginga, et al. (2010). Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59:1662-1669.
43. Hare JM, JH Traverse, TD Henry, N Dib, RK Strumpf, SP Schulman, G Gerstenblith, AN DeMaria, AE Denktas, et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54:2277-2286.
44. Prasad VK, KG Lucas, GI Kleiner, JAM Talano, D Jacobsohn, G Broadwater, R Monroy and J Kurtzberg. (2011). Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (ProchymalTM) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17:534-541.
45. Schwarz S, R Huss, M Schulz-Siegmund, B Vogel, S Brandau, S Lang and N Rotter. (2014). Bone marrowderived mesenchymal stem cells migrate to healthy and damaged salivary glands following stem cell infusion. Int J Oral Sci 6:154-161.
46. Youd M, C Blickarz, L Woodworth, T Touzjian, A Edling, J Tedstone, M Ruzek, R Tubo, J Kaplan and T Lodie. (2010). Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol 161:176-186.
47. Ettinger R, GP Sims, AM Fairhurst, R Robbins, YS da Silva, R Spolski, WJ Leonard and PE Lipsky. (2005). IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 175:7867-7879.
48. Tokoyoda K, S Zehentmeier, AN Hegazy, I Albrecht, JR Grun, M Lohning and A Radbruch. (2009). Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 30:721-730.
49. UccelliA, LMoretta andVPistoia. (2006). Immunoregulatory function ofmesenchymal stemcells. Eur J Immunol 36:2566-2573.
50. Fiuza UM and AM Arias. (2007). Cell and molecular biology of Notch. J Endocrinol 194:459-474.
51. Leung D, G Cachianes, W Kuang, D Goeddel and N Ferrara. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
52. Keck P, S Hauser, G Krivi, K Sanzo, TWarren, J Feder and D Connolly. (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312.
53. Spyridopoulos I, E Brogi, M Kearney, AB Sullivan, C Cetrulo, JM Isner and DW Losordo. (1997). Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-Alpha: balance between growth and death signals. J Mol Cell Cardiol 29:1321-1330.
54. Nakao N, T Nakayama, T Yahata, Y Muguruma, S Saito, Y Miyata, K Yamamoto and T Naoe. (2010). Adipose tissuederived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Am J Pathol 177:547-554.
55. Wells A. (1999). EGF receptor. Int J Biochem Cell Biol 31:637-643.